Preview

Global Fabry Disease Market 2014-2018

Satisfactory Essays
Open Document
Open Document
327 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Global Fabry Disease Market 2014-2018
Global Fabry Disease Market 2014-20180280035Fabry disease is an inheritable lysosomal storage disease characterized by excessive accumulation of GL-3 in lysosomes. It results from the deficiency of α-Gal and can result in symptoms such as fatigue, angiokeratoma, tinnitus, kidney failure, heart disorders and anervous system problems. Fabry disease results from mutations in the GLA gene resulting in decreased activity or complete absence of α-Gal.
Covered in this Report0280035This report covers the present scenario and the growth prospects of the Global Fabry Disease market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of various innovator drugs available in the market for the treatment of Fabry disease.
The report also presents the vendor landscape and a corresponding detailed analysis of the major vendors in the Global Fabry Disease market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.
View our full TOC hereKey Regions
EMEA
APAC
Americas
Key Vendors
Genzyme Corp.
Shire plc
Other Prominent Vendors
Amicus Therapeutics
ISU AbxisJCR Pharmaceuticals
Protalix BiotherapeuticsSumitomo Dainippon Pharma
Key Market Driver
Special Provisions for Orphan Drugs
For a full, detailed list, view our report.
Key Market Challenge
Limited Patient Population
For a full, detailed list, view our report.
Key Market Trend
Regulatory Assistance in Emerging Nations
For a full, detailed list, view our report.
Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses
Continue Reading
View Writing Issues

You May Also Find These Documents Helpful

  • Good Essays

    Scott Deter And Ventria Case Study Summary
    • 459 Words
    • 2 Pages

    Scott Deter And Ventria Case Study Summary

    A dialog between Ventria and its stakeholders offered the options of prioritizing their long list of projects to the one or two with the greatest likelihood of successful commercialization. Analyzing the medical activate proteins to determine which would be which would be a more successful use for the company. Didn’t meet the demonstrated need was there other company’s already proving this particular product and the methods of…

    • 459 Words
    • 2 Pages
    Good Essays
    Read More
  • Good Essays

    Medmmune Case Study Essay
    • 678 Words
    • 3 Pages

    Medmmune Case Study Essay

    However, since drugs typically see declining sales the longer they are on the market, pharmaceutical and biotechnology companies always depend on the continuous development and approval of new medications. While tax credits and research grants are available to companies that serve rare diseases, as an incentive to undertake the costly development process for drugs that will not be as widely marketable as those that cater to mass diseases, MedImmune has considered acquiring another biotechnology firm to expand its market share.…

    • 678 Words
    • 3 Pages
    Good Essays
    Read More
  • Satisfactory Essays

    GIRS International Reimbursement Analysis
    • 143 Words
    • 1 Page

    GIRS International Reimbursement Analysis

    The GIRS International Reimbursement Beacon services consolidates and coordinates International and U.S. reimbursement and market access strategies for our clients. Our experts in technology assessment, outcomes strategies, pricing, market access, and health economics all collaborate to help clients develop solid reimbursement strategies for commercializing new Products in Europe, Canada, South America, Asia, and Australia. Evidence requirements, market launch sequences, and pricing decisions vary from country to country. Without a guide like The GIRS International Reimbursement Beacon team that sheds light on market access requirements and strategies, it can be difficult to navigate stakeholder requirements from country to country. Our…

    • 143 Words
    • 1 Page
    Satisfactory Essays
    Read More
  • Good Essays

    Gaucher Disease
    • 381 Words
    • 2 Pages

    Gaucher Disease

    I learned to never be quick to judge a person when you never know what a person is going through! Gaucher disease is a receivable inherited lysosomal storage disease. This characterization makes tone by bruising of bones because they are weak and derive of pain. The sickness that deliberates fatigue, anemia that undergoes pain, low blood platelet count that will be harder flowing, and growth of the liver and spleen. These visceral and neurologic symptoms are causing disruption of the lysosomes because of accumulation. The accumulation will cause damage to the organs such as spleen, liver, and brain. As we all know the location of lysosomes are in the cell that contains enzymes that digest and separate the cell after its death. The hereditary deficiency, meaning that it passes along with the families of the enzyme glucocerebrosidase which act on glucocerebroside that will collect.…

    • 381 Words
    • 2 Pages
    Good Essays
    Read More
  • Satisfactory Essays

    Amicus Therapeutics Case Study
    • 346 Words
    • 2 Pages

    Amicus Therapeutics Case Study

    alone battle Fabry Disease; moreover, Amicus Therapeutics believes that this sets a sound stage for further development of the new drug Migalastat.…

    • 346 Words
    • 2 Pages
    Satisfactory Essays
    Read More
  • Satisfactory Essays

    Ethics Case Study
    • 573 Words
    • 2 Pages

    Ethics Case Study

    It takes $200 million in research and 12 years to bring the average drug to market; the decision to pursue research is a complex one. Since resources are finite, dollars and time have to go to projects that hold the most promise, in terms of both making money so a company can continue to exist and alleviating human suffering. This is an especially delicate issue when it comes to rare diseases, when a drug company's investment could probably never be recouped because the number of people who would buy the drug is so small. The…

    • 573 Words
    • 2 Pages
    Satisfactory Essays
    Read More
  • Satisfactory Essays

    Fabry Disease Research Paper
    • 160 Words
    • 1 Page

    Fabry Disease Research Paper

    The genetic disorder I chose was the Fabry disease.The other names they have for this disorder is alpha-galactosidase alpha.The thing that causes the disorder is the cause of lack or a faulty enzyme needed to metabolize lipids.If there are prenatal tests for this disorder then that means childhood disorders,including autism and Rett syndrome,caused by impairments in brain development.This disorder is treated by a test that measures leukocyte alpha-Gal A enzyme activity.…

    • 160 Words
    • 1 Page
    Satisfactory Essays
    Read More
  • Best Essays

    Pfizer Industry Review
    • 4325 Words
    • 18 Pages

    Pfizer Industry Review

    Since the 1950s, the global pharmaceutical industry has evolved from “…a collection of several hundred, small, barely profitable firms to as small group of large, highly profitable firms” (Younkin, 2008, para. 1). This evolution has resulted in an oligopoly market structure with a few large firms, and significant barriers to market entry. In the last 20 years, pharmaceutical consolidation has continued with both vertical and horizontal mergers that have further shrunk the market. Since 1995, Pfizer has merged with five pharmaceutical firms (Industry Brief, 2003) in an attempt to increase its research and development divisions and to offset declines in new product development; increases in generic competition; and the emergence of bio-pharmaceutical firms (BCC Research, 2004). Although pharmaceutical firms no longer view mega mergers as “…a cure-all for [their] innovation drought” (Simons, 2007, para. 1), this trend towards consolidation is expected to continue, with firms focusing “…on targeted acquisitions and alliances with smaller…more innovative drug makers and biotechs” (Simons, 2007, para. 10).…

    • 4325 Words
    • 18 Pages
    Best Essays
    Read More
  • Good Essays

    Fabry Disease Essay
    • 465 Words
    • 2 Pages

    Fabry Disease Essay

    Your assignment is to write a short report to this woman. This report should describe what is known about the genetic basis of this trait (OMIM number, inheritance, chromosomal location, gene function, metabolic basis, treatment, etc.). What is the probability that a child of this woman will be affected? What is the probability that one of her children will be a carrier? The answer to this question will be affected by many factors (the population frequency of the allele responsible for this trait, the mode of inheritance, etc.). As the frequencies of many diseases vary across human populations, you are free to choose from which population the woman is a member. Please clearly state her assumed population origin in your report.…

    • 465 Words
    • 2 Pages
    Good Essays
    Read More
  • Satisfactory Essays

    Gaucher Disease Research Paper
    • 212 Words
    • 1 Page

    Gaucher Disease Research Paper

    Many problems can be caused by difficulties in the lysosomes of our cells. An example of a disease that is caused from the malfunction or improper working of the lysosome is the lysosomal storage disease. Lysosomal storage disease is a group of disorders that affect specific enzymes in a specific location that normally break down items for reuse in the cells. When these enzymes stop working or don’t work properly, they can build up and eventually become toxic. This process occurs in the lysosomes of our cells. There are many different lysosomal storage diseases, an example being the Gaucher disease.…

    • 212 Words
    • 1 Page
    Satisfactory Essays
    Read More
  • Good Essays

    Gaucher Disease
    • 374 Words
    • 2 Pages

    Gaucher Disease

    Gaucher is a rare, inherited metabolic disorder in which deficiency of the enzyme glucocerebrosidase results in the accumulation of harmful quantities of certain fats (lipids). It can have serious effects on numerous body organs including the liver, spleen, bones and central nervous system.…

    • 374 Words
    • 2 Pages
    Good Essays
    Read More
  • Powerful Essays

    Genzyme - Where to from Here?
    • 1889 Words
    • 8 Pages

    Genzyme - Where to from Here?

    Considered a leader in the biotechnology industry, Genzyme has come a long way since its inception as a supplier of basic chemicals and reagents in 1981. As a leader in the development of orphan drugs, Genzyme realized revenues of almost $4B in 2007. Greater than 30% of its revenue in 2007 is attributed to the sales of drugs that target orphan diseases, such as Cerezyme, a novel Genzyme drug used to treat Gaucher disease. Due to the lack of previous research on orphan diseases, the development of drugs in this area is costly, requiring Genzyme to charge outrageous sums of money for treatment. For example, Cerezyme costs $50-200K per year per patient, an amount of money that is often well beyond the reach of patients suffering from Gaucher. To bridge the gap between the cost of Cerezyme and the patient’s ability to pay, Genzyme has to rely on government agencies to shoulder the cost for its citizens. Understanding that government subsidies are crucial to realizing any profit with their orphan disease drugs, Genzyme has developed strong relationships with NGO’s and government health-care agencies to create a culture of caring at Genzyme that they leverage to convince governments around the world to pay for patient medication. With such a large piece of their revenue being generated by these drugs, Genzyme has vested interest in ensuring this extremely profitable side of their business is positioned strongly in the global market. Thus, Genzyme has been able to generate revenue by increasing the willingness of their customers, mainly government agencies, to pay.…

    • 1889 Words
    • 8 Pages
    Powerful Essays
    Read More
  • Good Essays

    Biosimilars Market worth $1,954 Million by 2018
    • 588 Words
    • 3 Pages

    Biosimilars Market worth $1,954 Million by 2018

    The “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018”, provides a detailed overview of the major drivers,restraints, challenges, opportunities, current market trends, and strategies impacting the global biosimilars market along with the estimates and forecasts of the revenue and share analysis.…

    • 588 Words
    • 3 Pages
    Good Essays
    Read More
  • Good Essays

    Pharm Notes
    • 421 Words
    • 2 Pages

    Pharm Notes

    The Fabry Disease is a hereditary disorder, caused by the lack of or faulty enzyme needed to metabolize lipids, fat-like substances that include oils, waxes, and fatty acids. The enzyme is known as ceramide trihexosidase, also called alphagalactosidase A. The mutation of the gene causes a build up to harmful levels in the eyes, kidneys, autonomic nervous system, and cardiovascular system. It is an x-linked recessive inheritance. Therefore it is the females that carry it. The ones who are mostly affected by this disease are the males. Female’s carriers, though, may develop angiokeratomas and may have problems with burning pains. Very few of the carriers may also have kidney or heart problems. This disease occurs in 1 out of 40,000 to 60,000 people.…

    • 421 Words
    • 2 Pages
    Good Essays
    Read More
  • Satisfactory Essays

    Global Cardiac Biomarkers Market 2014-2018
    • 384 Words
    • 2 Pages

    Global Cardiac Biomarkers Market 2014-2018

    Covered in this Report0280035This report covers the present scenario and the growth prospects of the Global Cardiac Biomarkers market for the period 2014-2018. To calculate the market size, the report considers revenue generated through sales of devices and assays used for cardiac biomarkers to diagnose various CVDs.…

    • 384 Words
    • 2 Pages
    Satisfactory Essays
    Read More